WallStSmart

Medtronic PLC (MDT)vsNeuroone Medical Technologies Corp (NMTC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 278845% more annual revenue ($35.48B vs $12.72M). MDT leads profitability with a 13.0% profit margin vs -52.2%. MDT earns a higher WallStSmart Score of 61/100 (C+).

MDT

Buy

61

out of 100

Grade: C+

Growth: 4.7Profit: 6.5Value: 6.0Quality: 4.8
Piotroski: 2/9

NMTC

Avoid

27

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 7.0
Piotroski: 5/9Altman Z: -8.06
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MDTUndervalued (+10.3%)

Margin of Safety

+10.3%

Fair Value

$89.60

Current Price

$81.67

$7.93 discount

UndervaluedFair: $89.60Overvalued

Intrinsic value data unavailable for NMTC.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$94.69B9/10

Large-cap with strong market position

Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$2.08B8/10

Generating 2.1B in free cash flow

NMTC2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
72.5%10/10

Revenue surging 72.5% year-over-year

Debt/EquityHealth
0.0410/10

Conservative balance sheet, low leverage

Areas to Watch

MDT2 concerns · Avg: 2.5/10
Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-11.8%2/10

Earnings declined 11.8%

NMTC4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$29.65M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-123.6%2/10

ROE of -123.6% — below average capital efficiency

Free Cash FlowQuality
$-1.37M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin. PEG of 1.29 suggests the stock is reasonably priced for its growth.

Bull Case : NMTC

The strongest argument for NMTC centers on Revenue Growth, Debt/Equity. Revenue growth of 72.5% demonstrates continued momentum.

Bear Case : MDT

The primary concerns for MDT are Piotroski F-Score, EPS Growth.

Bear Case : NMTC

The primary concerns for NMTC are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

MDT profiles as a value stock while NMTC is a hypergrowth play — different risk/reward profiles.

MDT carries more volatility with a beta of 0.63 — expect wider price swings.

NMTC is growing revenue faster at 72.5% — sustainability is the question.

MDT generates stronger free cash flow (2.1B), providing more financial flexibility.

Bottom Line

MDT scores higher overall (61/100 vs 27/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Neuroone Medical Technologies Corp

HEALTHCARE · MEDICAL DEVICES · USA

NeuroOne Medical Technologies Corporation is a medical technology company. The company is headquartered in Eden Prairie, Minnesota.

Visit Website →

Want to dig deeper into these stocks?